U.S. markets closed
  • S&P 500

    3,819.72
    -50.57 (-1.31%)
     
  • Dow 30

    31,270.09
    -121.43 (-0.39%)
     
  • Nasdaq

    12,997.75
    -361.04 (-2.70%)
     
  • Russell 2000

    2,207.79
    -23.72 (-1.06%)
     
  • Crude Oil

    61.21
    +1.46 (+2.44%)
     
  • Gold

    1,713.60
    -20.00 (-1.15%)
     
  • Silver

    26.25
    -0.63 (-2.36%)
     
  • EUR/USD

    1.2067
    -0.0020 (-0.17%)
     
  • 10-Yr Bond

    1.4700
    +0.0550 (+3.89%)
     
  • GBP/USD

    1.3951
    -0.0006 (-0.04%)
     
  • USD/JPY

    106.9960
    +0.2860 (+0.27%)
     
  • BTC-USD

    50,976.59
    +3,341.42 (+7.01%)
     
  • CMC Crypto 200

    1,019.04
    +30.94 (+3.13%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that Chris Peetz, president and chief executive officer at Mirum will present at the virtual Canaccord Genuity 40th Annual Growth Conference on August 13, 2020 at 3:00pm ET.

A live audio webcast and an archive of the presentation will be available in the Investors & Media section of the company website at ir.mirumpharma.com.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). For more information, visit mirumpharma.com. Follow Mirum on Twitter, Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200807005365/en/

Contacts

Investor contact:
Ian Clements, Ph.D.
ir@mirumpharma.com

Media contact:
Erin Murphy
media@mirumpharma.com